178 related articles for article (PubMed ID: 33734131)
1. Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab.
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
Chin Med J (Engl); 2021 Mar; 134(11):1329-1334. PubMed ID: 33734131
[TBL] [Abstract][Full Text] [Related]
2. Optimal dosage of rituximab for children with Burkitt lymphoma.
Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
[TBL] [Abstract][Full Text] [Related]
3. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
[TBL] [Abstract][Full Text] [Related]
4. [Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
Wang BT; Dang HB; Wei YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):529-534. PubMed ID: 32319391
[TBL] [Abstract][Full Text] [Related]
5. [Clinical and prognostic analysis of 186 children with Burkitt's lymphoma].
Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
Zhonghua Er Ke Za Zhi; 2018 Aug; 56(8):605-610. PubMed ID: 30078243
[No Abstract] [Full Text] [Related]
6. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
[No Abstract] [Full Text] [Related]
7. [Clinical analysis of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma].
Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):633-638. PubMed ID: 31495128
[No Abstract] [Full Text] [Related]
8. Burkitt lymphoma after solid-organ transplant: Treatment and outcomes in the paediatric PTLD collaborative.
Afify Z; Orjuela-Grimm M; Smith CM; Dalal M; Ford JB; Pillai P; Robles JM; Reddy S; McCormack S; Ehrhardt MJ; Ureda T; Alperstein W; Edington H; Miller TP; Rubinstein JD; Kavanaugh M; Bukowinski AJ; Friehling E; Rivers JM; Chisholm KM; Marks LJ; Mason CC
Br J Haematol; 2023 Feb; 200(3):297-305. PubMed ID: 36454546
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of 40 children with Burkitt's and Burkitt-like lymphoma].
Zhang YH; Duan YL; Yang J; Jin L; Zhou CJ; Gao ZF
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):209-14. PubMed ID: 19099711
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
[TBL] [Abstract][Full Text] [Related]
11. [Clinical pathologic characteristics and treatment outcomes of 19 relapsed pediatric B-cell lymphoma].
Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Ma XL; Zhang YH
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):748-753. PubMed ID: 29050112
[No Abstract] [Full Text] [Related]
12. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
Zayac AS; Evens AM; Danilov A; Smith SD; Jagadeesh D; Leslie LA; Wei C; Kim SH; Naik S; Sundaram S; Reddy N; Farooq U; Kenkre VP; Epperla N; Blum KA; Khan N; Singh D; Alderuccio JP; Godara A; Yazdy MS; Diefenbach C; Rabinovich E; Varma G; Karmali R; Shao Y; Trabolsi A; Burkart M; Martin P; Stettner S; Chauhan A; Choi YK; Straker-Edwards A; Klein A; Churnetski MC; Boughan KM; Berg S; Haverkos BM; Orellana-Noia VM; D'Angelo C; Bond DA; Maliske SM; Vaca R; Magarelli G; Sperling A; Gordon MJ; David KA; Savani M; Caimi P; Kamdar M; Lunning MA; Palmisiano N; Venugopal P; Portell CA; Bachanova V; Phillips T; Lossos IS; Olszewski AJ
Haematologica; 2021 Jul; 106(7):1932-1942. PubMed ID: 33538152
[TBL] [Abstract][Full Text] [Related]
14. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
15. [Clinical features and prognosis of children with Burkitt's lymphoma: an analysis of 62 cases].
Wang YC; DU WC; Yin CY; Gong X; Li YF
Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):561-565. PubMed ID: 35644197
[TBL] [Abstract][Full Text] [Related]
16. Successful salvage chemotherapy for isolated central nervous system (CNS) relapse in Burkitt lymphoma: monocentric experience of 3 pediatric patients.
Baleydier F; Pondarre C; Pages MP; Mialou V; Kebaili K; Pracros JP; Bertrand Y
J Pediatr Hematol Oncol; 2008 Dec; 30(12):972-5. PubMed ID: 19131795
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin's Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease.
Huang S; Jin L; Yang J; Duan Y; Zhang M; Zhou C; Zhang YH
Technol Cancer Res Treat; 2021; 20():15330338211016372. PubMed ID: 34060372
[TBL] [Abstract][Full Text] [Related]
18. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
Chamuleau MED; Stenner F; Chitu DA; Novak U; Minnema MC; Geerts P; Stevens WBC; Zenz T; van Imhoff GW; Wu KL; Demandt AMP; Kersten MJ; Terpstra WE; Tick LW; Deeren D; Van Den Neste E; Gregor M; Veelken H; Böhmer LH; Caspar CB; Mutsaers P; Refos JM; Sewsaran R; Fu L; Seefat RL; Uyl-de Groot CA; Dirnhofer S; Van Den Brand M; de Jong D; Nijland M; Lugtenburg P
Lancet Haematol; 2023 Dec; 10(12):e966-e975. PubMed ID: 37922925
[TBL] [Abstract][Full Text] [Related]
19. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
20. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
